Lippis Daniel J. 4

What Happened
Daniel J. Lippis, Corporate Vice President (TAVR) at Edwards Lifesciences (EW), was granted 12,820 restricted stock units (RSUs) on Feb 12, 2026 (reported on Form 4). To satisfy tax withholding tied to the award, 258 shares were surrendered on Feb 16 and 198 shares on Feb 17 at $75.87 per share (cash value $19,574 and $15,022 respectively), for a total withholding of $34,596. This was an equity award (A) with tax-withholding disposals (F), not an open‑market sale or purchase.

Key Details

• Grant: 12,820 RSUs granted on 2026-02-12 (acquired at $0.00 per share).
• Tax withholding: 258 shares on 2026-02-16 and 198 shares on 2026-02-17 at $75.87/share (total ~$34,596).
• Net change from these transactions: +12,820 RSUs granted less 456 shares withheld = net +12,364 RSUs granted (these RSUs are unvested).
• Vesting/footnote: These RSUs vest in four equal annual installments beginning one year after the grant date (per footnote F1).
• Filing: Form 4 filed 2026-02-17 covering transactions dated 2026-02-12 through 2026-02-17; the filing shows changes in beneficial ownership only.

Context: This was an equity award (RSUs) rather than a purchase or sale. The withheld shares were used to cover tax obligations (transaction code F), a routine administrative step that does not by itself indicate insider sentiment. The RSUs are subject to future vesting, so they are not immediately liquid shares.